Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.

ABSTRACT:

Importance

Immune-related adverse events (irAEs) have been associated with the efficacy of PD-1 (programmed cell death protein 1) inhibitors in patients with melanoma, but whether such an association exists for non-small-cell lung cancer (NSCLC) has remained unknown.

Objective

To evaluate the relation of irAEs to nivolumab efficacy in NSCLC.

Design, setting, and participants

In this study based on landmark and multivariable analyses, a total of 134 patients with advanced or recurrent NSCLC who were treated with nivolumab in the second-line setting or later between December 2015 and August 2016 were identified from a review of medical records from multiple institutions, including a university hospital and community hospitals. Data were updated as of December 31, 2016.<

SUBMITTER: Haratani K 

PROVIDER: S-EPMC6583041 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature